Futura Medical Live Discussion

lawven2 29 Oct 2019

Thoughts on Future Market Cap @ Smashing1 The main thing for us people at the mercy of FUM is that Mr/Mrs/Ms/Miss T Adams hasn’t taken any profit whatsoever to date. Rspectful Greetings. ALL. My first post on FUM’s. i do hope the link opens for you, if you have not seen it before, but are interested. - LLV TR-1: Standard form for notification of major holdings: [link] NOTIFICATION OF MAJOR HOLDINGS (But this may wrap-around and not hold tabular format!) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Futura Medical PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer Reason for the notification (please mark the appropriate box or boxes with an “X”) An acquisition or disposal of voting rights x An acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other (please specify)iii: Details of person subject to the notification obligationiv Name Mr. T Adams City and country of registered office (if applicable) Exeter, United-Kingdom Full name of shareholder(s) (if different from 3.)v Name City and country of registered office (if applicable) Date on which the threshold was crossed or reachedvi: 24/10/2019 Date on which issuer notified (DD/MM/YYYY): 24/10/2019 Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights of issuervii Resulting situation on the date on which threshold was crossed or reached 6.98% 6.98% 204,660,267 Position of previous notification (if applicable) 7.06% 7.06% Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii A: Voting rights attached to shares Class/type of shares ISIN code (if possible) Number of voting rightsix % of voting rights Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) GB0033278473 14,288,415 6.98% SUBTOTAL 8. A 14,288,415 6.98%

fx2452 28 Oct 2019

Thoughts on Future Market Cap So far, it’s all looking as you’d want it to. Likely the next data release is the big one… GLA

Aberdeen_investor 28 Oct 2019

Thoughts on Future Market Cap So we see that the study evaluated doses of 0.01, 0.075, 0.25 and 0.6 mg (0.2%) of MED2005. Significant differences in penile blood flow were noted only in the 0.6mg dose (0.2%) which was the one used for phase 2. Yet another reason why it was deemed as the minimum effective dose and why there is a high likelihood of the higher doses improving blood flow even further!

smashing1 25 Oct 2019

Thoughts on Future Market Cap The main thing for us people at the mercy of FUM is that Mr/Mrs/Ms/Miss T Adams hasn’t taken any profit whatsoever to date. Just think, when the price was 47p, that’s a lot of £s, and at 27p it still is.

fx2452 25 Oct 2019

Thoughts on Future Market Cap Could be! Perhaps we’ll see the former Arsenal player early next year appear as a BBC pundit dressed in Aberdeen’s suit?! Am hoping ‘T Adams’ will have a lot more ‘major share holder’ company some time next week off the back of Futura’s presentation at the US conference happening at the moment. If Americans realise what a mouth watering Risk:Reward this UK company is, who knows what could happen pre the 3a results. Fingers crossed we’ll all be buying one of Aberdeen’s suits soon…

smashing1 25 Oct 2019

Thoughts on Future Market Cap The 7% stake must have cost around £1m. Intriguing, but don’t suppose we’ll ever know. My bet is it’s Tony Adams, once of Arsenal and England …

fx2452 25 Oct 2019

Thoughts on Future Market Cap I think it highly unlikely it’s an individual (especially on a university salary) that owns £3.5m of FUM stock. I’m not saying it’s definitely Adams plc either. Just a possibility (that looks ‘interesting’)

smashing1 25 Oct 2019

Thoughts on Future Market Cap I don’t think so. If you google: t adams exeter investegate

fx2452 25 Oct 2019

Thoughts on Future Market Cap Interesting… the other (cat fighting) board reminded that a “T Adams” owns 7% of FUM. Having a dig around, is this the “T Adams”?: [link] Our Price/book value currently stands at 5.7.

Aberdeen_investor 25 Oct 2019

Thoughts on Future Market Cap I’m sure I speak for everyone… we all look forward to having you onboard too Tony. And your opinion is welcome too. Thankfully we have some level of sanity on this board where we can agree to disagree and not take it personally! GLA

TonyDeadeye 25 Oct 2019

Thoughts on Future Market Cap Some fair points but I agree, Aberdeen, that we’ll agree to disagree. I have “liked” the opinions even though I don’t entirely agree but I respect your points of view. I still remain to be convinced, however. I think last year’s fund raise was a desperate patch up with no real forward thinking, and reliance placed on some progress with TPR. Not only would TPR have brought some kind of milestone payment (though admittedly not quite enough to plug the gap) it would have restored institutional investor confidence. I know I keep banging on about the IIs, but they’re extremely important and their absence and the SP weakness IMO suggests negative activity behind the scenes. On a concluding note I think FUM will be in a position of weakness in negotiating any deal/funding on completion of Phase 3 because funds will be low, and 3rd parties will realise this. And I also thought this strategy adopted by Mr Barder was to maintain control but a non-dilution funding would hand that control over (?) I’m not trying to scare folk off, I’m simply putting my own view across why I think FUM is so unloved at the moment. Also in my previous 12 years as a holder whenever I “expected” the SP to rise, it never did! A genuine GLA and hopefully one day I can re-join the party.

trump53 24 Oct 2019

Thoughts on Future Market Cap “I would expect that they wouldn’t want their competitors to get the rights to this” The very reason I am so keen to invest in FUM. Futura have gone to a great deal of trouble and expense to ensure that all interested parties are aware that MED2005 is the next and best product with which to reduce the debilitating effects of ED in future. Regulators seem happy so far, with MED2005’s OTC potential. If available OTC, purchasers who don’t know what Erectile Dysfunction is could purchase MED2005, and the market size should balloon. Interested parties wishing to profit from a bonanza far bigger than viagra, have two priorities as I see it: 1 Does the phase 3a trial meet its primary and secondary outcomes? 2 How can we make sure we get the phone call from Barder when he decides who he wants to work with in a buyout or a licensing scenario? There is no competing technology, so there is only one shot at manufacturing / distributing a product that makes viagra an unpleasant experience in comparison. Ensuring their Pharma is the one Barder chooses, is pivotal to the career of all interested pharma MD’s. Behind the scenes this should be warming up nicely now the phase 3 results are being unscrambled. Despite not hearing of specific interest, I believe Barders’ statements that there has been a great deal of interest in MED2005, could be an understatement. I am finding difficulty finding the time to post, but had to respond tonight to some great posts. Thanks for the Great Bullet Points Aberdeen.

fx2452 24 Oct 2019

Thoughts on Future Market Cap Just to put the “why didn’t we raise enough for both 3a & 3b in one go” to bed… If we raised for example twice the capital at the last fundraising , this would have resulted in around twice the dilution. With good or excellent 3a results, I’m confident that we’ll be able to raise a similar amount as we did, but for a fraction of the dilution (thanks to the major de-risking of the offering).

fx2452 24 Oct 2019

Thoughts on Future Market Cap I completely concur with Aberdeen regarding the fundraising. One of the fundamentals about fundraising is that the more risk involved, the more equity you have to give away. Hence, when fundraising at seed stage (with just an idea and no data), this is the most expensive time. After phase 2, it’s been de-risked quite substantially. And here, after 3a results (assuming they’re good or excellent), the risk is hugely minimised. Therefore fundraising with good results in 2 months time, are a complete different ball game. Indeed, I remain of the opinion that with good or excellent results, they’ll be a sudden charge by the big players who want to have a hand in the ED market. This, as I would expect that they wouldn’t want their competitors to get the rights to this. Bear in mind, (from memory in around 1999) it cost around $100million to get a new drug to the market place from scratch! This is “a new drug” as opposed to a “blockbuster drug” (a blockbuster being defined as a drug with peak sales of $1bn or more per annum). The large Pharmas are in a constant battle to get new blockbuster drugs to the market place in order to replace blockbuster drugs that have expiration of their patents (& hence wide open to cheaper generic copies). With good or excellent results, (at the risk of sounding like a broken record), MED will be in “touching distance” of becoming a blockbuster. And my personal opinion is that the touted potential market size of around $1bn pa peak (prescription & over the counter) is very pessimistic! MED is just so much better than viagra etc that I am of the opinion that it would capture a much larger chunk of this huge market. The above is of course dependent upon good or excellent results at 3a. Only time will tell. And that time is very shortly upon us… GLA

Aberdeen_investor 24 Oct 2019

Thoughts on Future Market Cap In my view it would have been a huge mistake to raise all the funds in one go before phase 3 data was out. (But we can agree to disagree). Why? Because of the number of unanswered questions on phase 2 data. Having the hopefully good phase 3 data will clarify a lot of the questions and will allow a much much better price to be achieved IF funding is required from shareholders. Note, There is a possibility of no further funding requirement from shareholders. So what were the unanswered questions I keep on going on about? side effect profile of higher doses market size (will higher doses show increased efficacy on the mild to moderate and moderate group) how will the contraindicated patients respond? duration of sex? (I think the higher doses will help with this based on PK results) onset of action time? additional questions (from potential partners) that formed part of the questionnaire given to those participating ? the increase in the penile index function scores for the higher doses to get this as a primary treatment In order to come to an agreement regarding the net worth Futura Medical will have an opinion on the worth of MED. However phase 2 left so many questions unanswered that they were unable to justify it and that includes the potential market size. The pharma’s on the other hand will also have an idea of the market size but the gap between what one party wants and the other is able to pay (based on phase 2 data) was in my opinion far too wide. I feel it made much more sense to hold of raising the full funds as based on all the evidence and the PK study I feel we will be in a position of strength whilst last time with only phase 2 data in hand we were in a position of weakness. If the company has made the statement that they are looking at both dilutive and non dilutive source of funding then I trust that to be the case. All of this depends on the strength of the phase 3 results which I am expecting to be excellent. However Each to their own